Connect with others who understand.

sign up log in
About MyMSTeam

Relapsing-Remitting MS (RRMS) Treatments Explained

Updated on March 16, 2020

Article written by
Kelly Crumrin

As of January 2019, there were 18 different disease-modifying therapies (DMTs) approved by the U.S. Food and Drug Administration (FDA) for treating multiple sclerosis (MS).1 Each DMT has been proven in multiple clinical trials to reduce the frequency of clinical attacks (also called relapses, flare-ups, or exacerbations) and reduce the development of new lesions on the brain and spinal cord, which make up the central nervous system (CNS).2 Some DMTs have also been proven to slow the accumulation of disability.2 Overall, DMTs slow disease progression and might help keep relapsing-remitting multiple sclerosis (RRMS) stable.3 Some DMTs have also been approved to treat other types of MS, such as secondary progressive MS (SPMS) and clinically isolated syndrome.

With so many treatment options, how can someone diagnosed with RRMS know which MS treatment will be best for them? For some people, how a DMT is taken and how often it is taken are important factors. Some prefer a medication taken orally over one taken by injection or intravenous (IV) infusion. Others prefer a more convenient dosage schedule with medication taken only a few times a year.

It can also help to know how doctors view which DMTs should be prescribed first and how different classes of DMTs work.

Evaluating Risks and Benefits of DMTs

Treatments for RRMS, like all medications, have possible risks.3 Some side effects are more common, and others are extremely rare. Risk-averse people may prefer to avoid DMTs with a potential for serious side effects, even if those side effects occur very rarely. Others may prefer to focus on which DMT will be most effective in modifying the course of their RRMS, even if they carry a low risk for severe adverse effects. It is important to note that an individual’s risk for developing serious side effects is dependent on many factors. Your doctor can help you understand your risk for side effects with any medication.

Some DMTs have contraindications – circumstances that raise the risk for serious side effects in people with other health conditions. For instance, some DMTs are not recommended for people who test positive for John Cunningham virus – also known as JC virus – antibodies. Other DMTs may not be safe for people with liver dysfunction. If you have any other health problems or conditions, your doctor may avoid prescribing certain DMTs.

Doctors may recommend DMTs based on many factors. One important factor is RRMS disease activity. An individual’s RRMS may be active or not active.4 Active disease is defined as having had a clinical relapse or the detection of new lesions via magnetic resonance imaging (MRI) scan over a period of time, usually a year.4 Doctors may recommend different DMTs based on whether your RRMS is considered to be active or not active.

What Are First-Line and Second-Line Treatments for RRMS?

According to the Consortium of Multiple Sclerosis Centers (CMSC), a large membership organization of health care providers for those with MS, any approved DMT may be considered as an initial treatment for someone diagnosed with RRMS based on what is best for that individual.

Many doctors discuss DMTs for relapsing-remitting MS in terms of first-line and second-line treatments. First-line treatments are DMTs generally prescribed as an initial treatment for someone diagnosed with RRMS. Which treatments are considered first-line versus second-line is always evolving.5 In general, drugs with a higher risk for serious side effects are more likely to be considered as second- or third-line options.6

FIRST-LINE DMTS FOR RELAPSING-REMITTING MS
Disease-modifying treatment Method of administration Dosage schedule
Aubagio (Teriflunomide) Oral Once a day
Avonex (Interferon beta-1a) Injection Once a week
Betaseron (Interferon beta-1b) Injection Every other day
Copaxone (Glatiramer acetate) Injection Daily or three times a week
Extavia (Interferon beta-1b) Injection Every other day
Glatopa (Glatiramer acetate) Injection Daily or three times a week
Glatiramer acetate Injection Daily or three times a week
Ocrevus (Ocrelizumab) IV infusion Every six months
Plegridy (Peginterferon beta-1a) Injection Every two weeks
Rebif (Interferon beta-1a) Injection Three times a week
Tecfidera (Dimethyl fumarate) Oral Twice a day
Vumerity (Diroximel fumarate)* Oral Twice a day

Based on information sourced from: Treatment for MS. (n.d.). MS Focus Accessed February 2020, at https://msfocus.org/Get-Educated/Treatment-for-MS.aspx

*Based on information sourced from: Disease Modifying Therapies for MS. National Multiple Sclerosis Society. Accessed February 2020, at nationalMSsociety.org/DMT

Second-line or even third-line treatments may be recommended when it becomes evident that the current treatment is failing.5 Treatment failure can mean different things for different people with RRMS. It’s important to remember that no DMT can cure or completely stop multiple sclerosis.7 According to the CMSC, switching treatments may be considered when:

  • Your RRMS is not responding adequately to treatment. This is a subjective measurement, but may include a relapse, new or worsening lesions, or worsening results during a neurologic exam within a year of starting therapy.
  • You have significant side effects on the first therapy, or a new health concern or contraindication raises the risk for side effects.
  • You no longer have access to the first DMT.
  • You have trouble taking the first DMT or cannot tolerate its side effects.

SECOND-LINE DMTS FOR RELAPSING-REMITTING MS
Disease-modifying treatment Method of administration Dosage schedule
Gilenya (Fingolimod) Oral Once a day
Lemtrada (Alemtuzumab) IV infusion Five days in a row, then three days 12 months later
Mavenclad (Cladribine) Oral 10 pills in the first year, 10 pills in the second year
Mayzent (Siponimod) Oral Once a day
Novantrone (Mitoxantrone) IV infusion Every three months
Tysabri (Natalizumab) IV infusion Every four weeks

Based on information sourced from: Treatment for MS. (n.d.). MS Focus. Accessed February 2020, at https://msfocus.org/Get-Educated/Treatment-for-MS.aspx

How Does Each Class of Medications for RRMS Work?

Among the 18 DMTs approved for treating RRMS, there are nine mechanisms of action – in other words, different ways of working.1 Most DMTs modify different aspects of the immune system to prevent autoimmune attacks on the myelin that sheathes nerve fibers. Understanding how disease-modifying therapies work can provide insight into why your doctor recommends a different medication. For instance, if you are switching drugs because the DMT you have been taking has been ineffective, your doctor will likely recommend a drug with a different mechanism of action.1

HOW DIFFERENT DMTS WORK IN RELAPSING-REMITTING MS
Disease-modifying treatments Believed mechanism of action
Betaseron (Interferon beta-1b)
Extavia (Interferon beta-1b)
Inhibit T cell numbers and activation. Beta interferons encourage the activity of regulatory T cells and the death of T cells involved in autoimmunity. They help prevent the migration of white blood cells across the blood-brain barrier.

Avonex (Interferon beta-1a)

Rebif (Interferon beta-1a)

Plegridy (Peginterferon beta-1a)

Similar to Interferon beta-1b, above.

Copaxone (Glatiramer acetate)

Glatiramer acetate

Glatopa (Glatiramer acetate)

Encourage and activate helper T cells and regulatory T cells. Support the growth and development of neurons (brain cells). May also target antigen-presenting cells involved in autoimmune attacks.
Gilenya (Fingolimod) Blocks white blood cells from leaving lymph nodes, reducing their numbers in the CNS.
Aubagio (Teriflunomide) Reduces the number of activated white blood cells in the CNS.
Tecfidera (Dimethyl fumarate) Vumerity (Diroximel fumarate)* Reduce inflammation involved in MS.
Tysabri (Natalizumab) Prevents white blood cells from migrating into inflamed tissues.
Mavenclad (Cladribine) Reduces the number of white blood cells, especially B cells.
Lemtrada (Alemtuzumab) Lowers the number of circulating B and T cells.
Ocrevus (Ocrelizumab) Encourages the destruction of B cells involved in MS attacks.

Based on information sourced from: CMSC Practical Guidelines for the Selection of Disease-Modifying Therapies in Multiple Sclerosis. Accessed February 2020 at https://cmscscholar.org/cmsc-practical-guidelines-for-the-selection-of-disease-modifying-therapies-in-ms/

*Based on information sourced from: FDA Approves Oral Vumerity (Diroximel Fumarate), Similar to Tecfidera, for Relapsing MS. (2019, October 30). Retrieved February 2020, from https://www.nationalmssociety.org/About-the-Society/News/FDA-Approves-Oral-Vumerity™-(Diroximel-Fumarate),

†Based on information sourced from: Otto, G. (2018, December 10). The story of cladribine reaches its climax. Retrieved February 2020, from https://www.nature.com/articles/d42859-018-00029-1

For people living with active RRMS, the only way to know whether a disease-modifying treatment will be effective is to begin taking it.8 Many people with RRMS find it necessary to switch to a different DMT over the course of their treatment.7

Making treatment decisions can be stressful and confusing. By joining MyMSTeam, you gain the support and insights of more than 144,000 members living with MS.

References

  1. CMSC Practical Guidelines for the Selection of Disease-Modifying Therapies in Multiple Sclerosis. Consortium of Multiple Sclerosis Centers. Accessed February 2020, at https://cmscscholar.org/cmsc-practical-guidelines-for-the-selection-of-disease-modifying-therapies-in-ms/
  2. Disease-Modifying Therapies for MS. National Multiple Sclerosis Society. Retrieved February 2020, from nationalMSsociety.org/DMT
  3. Starting Disease-Modifying Therapies for MS. (2018). American Academy of Neurology. Retrieved 2020, from https://www.aan.com/Guidelines/home/GuidelineDetail/898
  4. Lublin, F. D. (2014). New Multiple Sclerosis Phenotypic Classification. European Neurology, 72(s1), 1–5. doi: 10.1159/000367614. Retrieved February 2020, from https://www.karger.com/Article/FullText/367614
  5. Dörr, J., & Paul, F. (2015). The Transition From First-Line to Second-Line Therapy in Multiple Sclerosis. Current Treatment Options in Neurology, 17(6). doi: 10.1007/s11940-015-0354-5. Retrieved February 2020, from https://www.researchgate.net/publication/275526476_The_Transition_From_First-Line_to_Second-Line_Therapy_in_Multiple_Sclerosis
  6. Treatment for MS. (n.d.). MS Focus. Retrieved February 2020, from https://msfocus.org/Get-Educated/Treatment-for-MS.aspx
  7. Coyle, P. K. (2013). Switching Therapies in Multiple Sclerosis. CNS Drugs, 27(4), 239–247. doi: 10.1007/s40263-013-0042-5
  8. Derwenskus, J. (2011). Current Disease-Modifying Treatment of Multiple Sclerosis. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine, 78(2), 161–175. doi: 10.1002/msj.20239

Kelly leads the creation of content that educates and empowers people with chronic illnesses. Learn more about her here.

A MyMSTeam Member said:

Ditto, I been off Avonex 24+ yrs

edited, originally posted 3 days ago

hug (1)

Recent articles

Bsp af 6
Thousands of members of MyMSTeam connect with one another and read each other's stories to gain...

Four Books About Multiple Sclerosis You Should Read

Thousands of members of MyMSTeam connect with one another and read each other's stories to gain...
Mht video ms   covid 19 an interview  with  dr. aaron boster vertical04 carousel
Article written by Eric Peacock Medically reviewed by Dr. Aaron BosterAccording to Dr. Aaron...

MS Treatments and COVID-19: What to Discuss With Your Neurologist

Article written by Eric Peacock Medically reviewed by Dr. Aaron BosterAccording to Dr. Aaron...
Mht covid19 essentialupdates carousel
During the COVID-19 pandemic, MyMSTeam will provide summaries and links to articles of importance...

COVID-19 and Multiple Sclerosis (MS) Essential Updates

During the COVID-19 pandemic, MyMSTeam will provide summaries and links to articles of importance...
Signs and symptoms of spms
Article written by Nyaka Mwanza Secondary progressive multiple sclerosis (SPMS) is diagnosed in...

Signs and Symptoms of Secondary Progressive Multiple Sclerosis (SPMS)

Article written by Nyaka Mwanza Secondary progressive multiple sclerosis (SPMS) is diagnosed in...
Stem cell treatment for ms
Article written by Nyaka Mwanza Stem cell therapy is an emerging area of treatment that may hold...

Stem Cell Treatment for Multiple Sclerosis

Article written by Nyaka Mwanza Stem cell therapy is an emerging area of treatment that may hold...
Mht video how to talk to your doctor drexpertinterview carousel
Your doctor learns the most about your multiple sclerosis (MS) through what you tell them, not...

How to Talk to Your Doctor About MS: Advice From Dr. Aaron Boster

Your doctor learns the most about your multiple sclerosis (MS) through what you tell them, not...
Mht video areweclosetocureforms drexpertinterview carousel
Article written by Laurie Berger Medically reviewed by Aaron Boster, M.D.Will we ever see a cure...

Are We Close to a Cure for MS?: An Update from Dr. Aaron Boster

Article written by Laurie Berger Medically reviewed by Aaron Boster, M.D.Will we ever see a cure...
Early symptoms of ms
Article written by Mary K. Talbot Multiple sclerosis (MS) is an inflammatory autoimmune disease...

Early Symptoms of MS

Article written by Mary K. Talbot Multiple sclerosis (MS) is an inflammatory autoimmune disease...
Ms vs als understand the difference
Article written by Mary K. Talbot A slowing and unsteady gait would be unusual for a young or...

MS vs. ALS: Understanding the Difference

Article written by Mary K. Talbot A slowing and unsteady gait would be unusual for a young or...
Clinicially isolated syndrome vs ms
Article written by Nyaka Mwanza Clinically isolated syndrome (CIS) is a first episode of...

Clinically Isolated Syndrome (CIS) vs. MS

Article written by Nyaka Mwanza Clinically isolated syndrome (CIS) is a first episode of...
MyMSTeam My multiple sclerosis Team

Two Ways to Get Started with MyMSTeam

Become a Member

Connect with others who are living with multiple sclerosis. Get members only access to emotional support, advice, treatment insights, and more.

sign up

Become a Subscriber

Get the latest articles about multiple sclerosis sent to your inbox.

Not now, thanks

Privacy policy
MyMSTeam My multiple sclerosis Team

Thank you for signing up.

close